Announcements Trials
Browse Landscape

Phase

Phase 4 6Phase 3 4Phase 1 2

Status

Completed 4

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Dermatologic 4

Conditions

Keratosis, Actinic 4

Interventions

Carboplatin 315Paclitaxel 303Cisplatin 250Docetaxel 238pembrolizumab 230Gemcitabine 214Pemetrexed 158Capecitabine 147Rituximab 144Bevacizumab 142Dexamethasone 125Fluorouracil 121Cyclophosphamide 102Trastuzumab 100Doxorubicin 96Nivolumab 93Prednisone 92Oxaliplatin 90atezolizumab 75Leucovorin 72durvalumab 69130-nm albumin-bound paclitaxel 68Injections 66Lenalidomide 63Irinotecan 62Bortezomib 56Letrozole 54Topotecan 53Fulvestrant 53Drug Therapy 50

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 3 × INDUSTRY × Diclofenac × Clear all
NCT04552327 2024-03-05

KOHDIAK

Infectopharm Arzneimittel GmbH

Phase 3 Completed
631 enrolled
Dermatologic

Keratosis, Actinic

NCT01962987 2020-07-20

A Study Comparing Diclofenac Sodium Gel 3% to Solaraze® (Diclofenac Sodium) Gel 3% in the Treatment of Actinic Keratosis

Actavis Inc.

Phase 3 Completed
476 enrolled 10 charts
Dermatologic

Keratosis, Actinic

NCT03826550 2019-02-01

Therapeutic Equivalence of Diclofenac Sodium Gel 3% vs Solaraze ® in the Treatment of Actinic Keratosis

Encube Ethicals Pvt. Ltd.

Phase 3 Completed
655 enrolled
Dermatologic

Keratosis, Actinic

NCT02611804 2017-05-05

A Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled, Multicenter Study Comparing Diclofenac Sodium Gel, 3% to Solaraze® Gel, 3% in the Treatment of Actinic Keratosis on the Face or Bald Scalp

Teva Pharmaceuticals USA

Phase 3 Completed
492 enrolled
Dermatologic

Keratosis, Actinic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡